[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350400-105":59,"doc-detail-350400-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-farnesoid-x-receptor-bile-acid-axis-contributes-to-immune-evasion-in-gastric-cancer-and-its-inhibition-enhances-efficacy-of-anti-pd-l1-therapy","The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy","","Gastric cancer is a leading malignancy with high mortality, and its progression is shaped by the tumor microenvironment (TME), including diverse immune populations. Immune checkpoint signaling through PD-L1/PD-1 contributes to immune escape, but the determinants remain incompletely defined. The Farnesoid X receptor (FXR) is linked to TME regulation, yet the role of bile-acid signaling in malignant–immune interactions is unclear. This study shows FXR promotes PD-L1–mediated immune evasion and suggests FXR targeting to improve anti-PD-L1 therapy, especially in the intestinal subtype.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-farnesoid-x-receptor-bile-acid-axis-contributes-to-immune-evasion-in-gastric-cancer-and-its-inhibition-enhances-efficacy-of-anti-pd-l1-therapy/350400/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-farnesoid-x-receptor-bile-acid-axis-contributes-to-immune-evasion-in-gastric-cancer-and-its-inhibition-enhances-efficacy-of-anti-pd-l1-therapy/350400.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does the FXR-bile acid axis play in gastric cancer immune evasion?","Question",{"text":112,"@type":113},"The document links FXR to the regulation of immune-regulatory networks involving PD-L1/PD-1, promoting immune evasion in gastric cancer, particularly in the intestinal subtype.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the study methods support the relationship between FXR and PD-L1?",{"text":117,"@type":113},"RNA-seq comparing paired gastric mucosa shows subtype-associated FXR expression, and MS/MS profiling indicates dysregulated bile acid metabolism. In vitro experiments and patient-derived organoids show FXR ligands increase PD-L1 by activating FXR-responsive elements in the PD-L1 promoter.",{"name":119,"@type":110,"acceptedAnswer":120},"Why might inhibiting FXR improve anti-PD-L1 therapy effectiveness?",{"text":121,"@type":113},"Because FXR activation increases PD-L1 expression and enhances immune checkpoint–mediated suppression, targeting FXR is presented as a therapeutic approach to increase the efficacy of anti-PD-L1 treatment in intestinal gastric cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350400,1790192722,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Biochemistry and Biophysics Reports 46 (2026) 102653  \nContents lists available at ScienceDirect  \nBiochemistry and Biophysics Reports  \njournal [homepage:](homepage: www.elsevier.com/locate/bbrep)[ www.elsevier.com/locate/bbrep](homepage: www.elsevier.com/locate/bbrep)  \n| The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy\u003Cbr>Cristina Di Giorgio a,* , Michele Biagioli a , Silvia Marchian`o a , Carmen Massa a, Ginevra Lachi a, Ginevra Urbani a , Martina Bordonib, Rachele Bellini a, Luigi Cari a , Benedetta Sensini a, Maria Rosaria Sette a, Elva Morretta c , Maria Chiara Monti c ,\u003Cbr>Nicola Natalizi a , Luigina Graziosid, Eleonora Distruttid, Annibale Donini a, Angela Zampella b,**\u003Cbr>Stefano Fiorucci a,\u003Cbr>a University of Perugia, Department of Medicine and Surgery, Perugia, Italy b BAR PHARMACEUTICALS s.r.l., Via Gramsci 88/A, Reggio Emilia, 42124, Italy c University of Naples Federico II, Department of Pharmacy, Naples, Italy d Azienda Ospedaliera di Perugia, Perugia, Italy |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords:\u003Cbr>Farnesoid X receptor (FXR) gastric cancer Bile acids\u003Cbr>PD-L1\u003Cbr>Immune evasion\u003Cbr>Intestinal subtype |  | Gastric cancer ranks among the most prevalent malignancies globally and remains a major contributor to cancerrelated mortality. Its progression is profoundly shaped by the tumor microenvironment (TME), a dynamic milieu comprising extracellular matrix components, soluble mediators, and diverse non-malignant immune populations that collectively influence tumor initiation and evolution. Although immunotherapeutic strategies have recently attracted increasing attention in the management of solid tumors, including gastric carcinoma, the determinants of immune evasion in this context are still not fully delineated. The Farnesoid X receptor (FXR), a key nuclear receptor for bile acids, has recently been implicated in regulating TME composition and immune cell recruitment within gastric tumors. Yet, how bile acid signaling contributes to the bidirectional interactions between malignant and immune cells remains largely undefined. This study aimed to investigate the role of FXR in modulating immune-regulatory networks associated with PD-L1/PD-1 in gastric cancer. RNA-seq analysis of paired gastric mucosa from 39 gastric cancer patients revealed significant molecular differences between intestinal and diffuse tumors. FXR was overexpressed in the intestinal subtype and correlated with poor prognosis. MS/MS analysis demonstrated enrichment of tumor tissues by cholic acid and chenodeoxycholic acid compared to non-neoplastic pairs, supporting the hypothesis of dysregulated bile acid metabolism. In vitro, exposure of gastric cancer cell lines and patient-derived organoids to FXR ligands increased PD-L1 expression through direct binding of FXRresponsive elements in the PD-L1 promoter. Targeting FXR may offer a therapeutic approach to improve the effectiveness of immunotherapies in intestinal gastric cancer. |\n\n1. Introduction  \nGastric cancer is the fifth most common type of cancer and the third leading cause of cancer-associated mortality worldwide [1]. Despite advancements in treatment, the prognosis of locally advanced gastric cancer remains poor, and therapeutic options are limited. A critical factor in the progression of gastric cancer is the ability of cancer cells to escape the immune surveillance, primarily through the expression of  \nimmune checkpoint ligands such as the programmed death ligand 1 (PD-L1). PD-L1 binds to programmed death protein 1 (PD-1) on immune effector cells, such as T cells and NK cells, leading to cellular exhaustion, immune suppression and tumor progression [2].  \nThe development of immune checkpoint inhibitors, particularly antibodies targeting PD-1 and PD-L1, has significantly improved the survival of patients with various malignancies, including GC. ","cbCaimzl5JL73Dov","https://ap.wps.com/l/cbCaimzl5JL73Dov","pdf",14785724,"English","# Introduction\n## Immune evasion and PD-1/PD-L1 signaling in gastric cancer\n## Tumor microenvironment and anti-tumor immune effector cells\n## Bile acids, gut microbiota, and FXR in immune regulation\n# Study aims and overview","[{\"question\":\"What role does the FXR-bile acid axis play in gastric cancer immune evasion?\",\"answer\":\"The document links FXR to the regulation of immune-regulatory networks involving PD-L1/PD-1, promoting immune evasion in gastric cancer, particularly in the intestinal subtype.\"},{\"question\":\"How do the study methods support the relationship between FXR and PD-L1?\",\"answer\":\"RNA-seq comparing paired gastric mucosa shows subtype-associated FXR expression, and MS/MS profiling indicates dysregulated bile acid metabolism. In vitro experiments and patient-derived organoids show FXR ligands increase PD-L1 by activating FXR-responsive elements in the PD-L1 promoter.\"},{\"question\":\"Why might inhibiting FXR improve anti-PD-L1 therapy effectiveness?\",\"answer\":\"Because FXR activation increases PD-L1 expression and enhances immune checkpoint–mediated suppression, targeting FXR is presented as a therapeutic approach to increase the efficacy of anti-PD-L1 treatment in intestinal gastric cancer.\"}]","The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy | PDF",1790088880,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d37073bfbe4f10445bf43ec1a4016ace.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ce124679eca64e064f24cbbff57c0ca.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/315d9f5f0875a0beca7516ac315c69e5.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5ad55c46e36c37753f803e2b56196c1.webp",980,1306]